Double Trouble: When D&O Insurance Fails Executives in Dual-Capacity Roles
Time 4 Minute Read
Categories: D&O

A recent New Jersey Superior Court decision highlights the risks policyholders face when officers or directors serve dual-capacity roles, such as participating on boards for multiple companies.

In Mist Pharmaceuticals LLC v. Berkley Insurance Co., Mist Pharmaceuticals obtained a $2 million directors and officers liability policy from Berkley. The policy provided coverage for the company’s current and former officers and directors. It also contained a broad “capacity” exclusion that barred coverage for any claim:

based upon, arising out of, directly or indirectly resulting from or in consequence of, or in any way involving any Wrongful Act of an Insured Person serving in their capacity as director, officer, trustee, employee, member or governor of any other entity other than an Insured Entity or an Outside Entity, or by reason of their status as director, officer, trustee, employee, member or governor of such other entity.

Mist Pharmaceutical’s chairman of the board controlled several other entities, including a company named Akrimax, of which he was a director. Mist Pharmaceuticals entered into various agreements with third parties to acquire distribution rights for certain drugs. Those rights were then assigned to Akrimax, which would assist with the commercialization of the drug. One of those third-parties, CelestialRX, sued Mist Pharmaceuticals and its chairman, alleging that the chairman engaged in self-dealing that defrauded it. The lawsuit alleged that the use of Mist Pharmaceuticals as a “middleman” lacked a business purpose and that it was only involved so that the chairman could take a cut of the sales between CelestialRX and Akrimax.

Mist Pharmaceuticals sought coverage under its D&O policy. Berkley reserved its rights to deny coverage under the capacity exclusion, citing the lawsuit’s allegations that the chairman had been acting in a dual-capacity as both chairman of Mist Pharmaceuticals and a director of Akrimax. Mist Pharmaceuticals eventually sought Berkley’s consent to settle, which Berkley refused to provide. The lawsuit settled for $12 million without Berkley’s consent.

Mist Pharmaceuticals filed a declaratory judgment action against Berkley, seeking a declaration that the settlement was covered. The trial court granted summary judgment in Mist Pharmaceuticals’ favor, finding Berkley’s decision to withhold consent was unreasonable. The trial court did not analyze the capacity exclusion because it decided that Berkely breached its duty to indemnify, thereby waiving its policy defenses. 

Berkely appealed, and the New Jersey Superior Court reversed, finding the capacity exclusion did, in fact, exclude coverage under the policy. The appellate court noted that Berkley’s decision to withhold consent was not unreasonable in light of the capacity exclusion. 

Turning to the application of the exclusion, the court held that the lawsuit alleged the chairman was acting both in his capacity as a director for Akrimax, which is not an insured entity, and a shareholder of Mist Pharmaceuticals. His wrongful acts allegedly arose out of his conduct in a capacity other than as an executive of Mist Pharmaceuticals, the insured company. The court cited other decisions that similarly applied capacity exclusions, including the Eleventh Circuit’s decision in Langdale Co. v. National Union Fire Ins. Co. of Pittsburgh, Penn., 609 Fed. Appx. 578 (11th Cir. 2015). The court held that like the loss in Langdale, the loss claimed by Mist Pharmaceuticals under the policy “arose from and could not have occurred but for [the chairman’s] conduct in his capacity as a director of Akrimax,” triggering the capacity exclusion.

The court’s decision in Mist Pharmaceuticals highlights the breadth and pitfalls of capacity exclusions, which is one of several provisions that can be invoked to limit or exclude coverage where insured individuals are not sued solely in an insured capacity. Policyholders should review the terms of their policies and discuss them with their broker and coverage counsel to understand the availability and scope of potential coverage for individuals who may be targeted in claims alleging acts on behalf of both insured entities and uninsured entities to help avoid gaps in coverage.

  • Partner

    Geoff works closely with corporate policyholders and their directors and officers to resolve high-stakes insurance disputes. He leads the firm’s directors and officers (D&O) insurance and executive protection practice.

    As a ...

  • Associate

    Alice handles all aspects of insurance coverage and bad faith litigation and provides proactive counseling and coverage reviews for policyholders. She consults with corporate clients on coverage issues and provides advice ...

You May Also Be Interested In

Time 4 Minute Read

Colleges and universities have long sat at the crossroads of freedom of expression and societal change. As campus activism surges, they face growing pressure to protect their institutional missions while upholding students’ individual rights in an era of heightened scrutiny.

Time 1 Minute Read

If recent years have taught insurance practitioners anything, it is that the most consequential coverage disputes rarely turn on novelty alone. In 2025, courts continued to resolve high‑stakes insurance disputes by returning to first principles—examining when claims are related, how losses and occurrences are defined and aggregated, and how policy language allocates risk across time and conduct. D&O coverage and other core insurance law issues again occupied center stage, while decisions in property, cyber, and liability disputes reinforced a familiar theme: policy interpretation remains the decisive factor in determining whether coverage is available in an increasingly complex claims environment. As the decisions discussed below demonstrate, 2025 confirmed that even as risks evolve, coverage disputes remain grounded in careful, policy‑specific analysis.

Time 5 Minute Read

Directors and officers liability insurance is first and foremost protection against personal exposure of boards and management who are targeted in claims challenging their decisions in running the company. That’s why it is surprising how often dedicated “Side A” coverage—insurance coverage, subject to no self-insured retention, available exclusively for the benefit of directors and officers who are not indemnified by the company—is overlooked in placing and renewing D&O insurance programs. One recent Texas bankruptcy ruling, In re First Brands Group, LLC, No. 25-90399 (CML) (Bankr. S.D. Tex. Jan. 7, 2026), demonstrates just how powerful Side A protection can be. There, against strong objections from the creditors’ committee, the bankruptcy court granted motions by numerous former executives seeking relief from the automatic stay to recover D&O insurance proceeds, unlocking millions in Side A coverage to defend against private and governmental claims asserted in connection with the bankruptcy.

Time 4 Minute Read

Artificial intelligence is transforming how businesses operate—but with innovation comes new, complex risks. A recent lawsuit—Raine, et al. v. OpenAI, Inc., Docket No. CGC25628528 (Cal. Super. Ct. Aug 26, 2025)—spotlights this dynamic and highlights why tried-and-true insurance products are still a critical first line of defense.

On August 26, 2025, the parents of a 16-year-old boy sued OpenAI, its CEO Sam Altman, and certain employees and investors. They claim that ChatGPT contributed to their son’s suicide by encouraging suicidal conduct, providing instructions on how to commit suicide, and even offering assistance in tying the knot used by the boy in the noose that eventually took the boy’s life. According to the complaint, the boy told ChatGPT that he “intended to commit suicide.” Rather than dissuade the suicide, the complaint claims that ChatGPT offered to “help him write a suicide note,” stating “I’ll help you with it. Every word.” Based on this factual background, the lawsuit alleges design defects, inadequate warnings, and violations of California’s Unfair Competition Law. Importantly, these allegations are just that: allegations. The case is just beginning, meaning no proof or substantiation has yet been offered beyond the allegations.

Search

Subscribe Arrow

Recent Posts

Categories

Tags

Authors

Archives

Jump to Page